ArticlePress releasePHN-05552026-11-02 02:50 CT

Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026

Source · PR Newswire

TLDR

Ascletis announced two preclinical poster presentations on obesity candidates ASC48 and ASC37 at ObesityWeek 2026. The company reports that triple peptide agonist ASC37 showed a sixfold longer half-life than Retatrutide in nonhuman primates and weight loss in diet-induced obese mice.

01—Key points

01The presentations are scheduled for November 14, 2026, in Washington, DC.
02ASC48 is a small molecule GIPR agonist; ASC37 targets GLP-1R, GIPR and GCGR.
03The announcement describes laboratory and animal findings, without providing numerical weight-loss results.

Why it matters Editorial

The findings concern an obesity peptide candidate, but the reported evidence is preclinical rather than human trial data.

Read the original at PR Newswire↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.